MA55285A - Anticorps ciblant c5ar - Google Patents

Anticorps ciblant c5ar

Info

Publication number
MA55285A
MA55285A MA055285A MA55285A MA55285A MA 55285 A MA55285 A MA 55285A MA 055285 A MA055285 A MA 055285A MA 55285 A MA55285 A MA 55285A MA 55285 A MA55285 A MA 55285A
Authority
MA
Morocco
Prior art keywords
antibodies targeting
c5ar
targeting c5ar
antibodies
targeting
Prior art date
Application number
MA055285A
Other languages
English (en)
Inventor
Barbara Bachler-Konetzki
Winfried Elis
Tanja Herrmann
Julia Neugebauer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA55285A publication Critical patent/MA55285A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055285A 2019-03-14 2020-03-13 Anticorps ciblant c5ar MA55285A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19162759 2019-03-14

Publications (1)

Publication Number Publication Date
MA55285A true MA55285A (fr) 2022-01-19

Family

ID=65812165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055285A MA55285A (fr) 2019-03-14 2020-03-13 Anticorps ciblant c5ar

Country Status (14)

Country Link
US (1) US20220135658A1 (fr)
EP (1) EP3938393A1 (fr)
JP (1) JP2022524449A (fr)
KR (1) KR20210141988A (fr)
CN (1) CN113574072B (fr)
AU (1) AU2020235263A1 (fr)
BR (1) BR112021017860A2 (fr)
CA (1) CA3132771A1 (fr)
IL (1) IL286238A (fr)
MA (1) MA55285A (fr)
MX (1) MX2021011040A (fr)
SG (1) SG11202108761YA (fr)
TW (1) TW202041535A (fr)
WO (1) WO2020182974A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140553A (zh) * 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
WO2022057910A1 (fr) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Polythérapies ciblant des voies c5ar et pd-1/pd-l1
MX2023008302A (es) * 2021-01-13 2023-09-25 Visterra Inc Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
EP1144607B1 (fr) 1999-07-20 2008-12-17 MorphoSys AG Procedes permettant la presentation de (poly)peptides/proteines sur des particules bacteriophages au moyen de liaisons disulfure
ES2561828T3 (es) * 2002-01-25 2016-03-01 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP3103814A1 (fr) * 2007-11-26 2016-12-14 Bayer Intellectual Property GmbH Anticorps anti-mésothéline et utilisations associées
CN105963694B (zh) * 2010-04-30 2019-11-05 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法
CN105949313B (zh) 2011-03-29 2021-06-15 罗切格利卡特公司 抗体Fc变体
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
CN105392803B (zh) * 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
EP3158058B1 (fr) 2014-06-18 2019-04-17 MorphoSys AG Protéines de fusion et utilisations associées
SG11201912882QA (en) * 2017-06-23 2020-01-30 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity

Also Published As

Publication number Publication date
SG11202108761YA (en) 2021-09-29
US20240018225A1 (en) 2024-01-18
IL286238A (en) 2021-10-31
JP2022524449A (ja) 2022-05-02
CA3132771A1 (fr) 2020-09-17
TW202041535A (zh) 2020-11-16
AU2020235263A1 (en) 2021-09-02
MX2021011040A (es) 2021-12-10
CN113574072A (zh) 2021-10-29
BR112021017860A2 (pt) 2021-12-07
CN113574072B (zh) 2023-12-12
WO2020182974A1 (fr) 2020-09-17
EP3938393A1 (fr) 2022-01-19
US20220135658A1 (en) 2022-05-05
KR20210141988A (ko) 2021-11-23

Similar Documents

Publication Publication Date Title
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA47694A (fr) Anticorps anti-tigit
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA52366A (fr) Anticorps anti-tl1a optimisés
MA52212A (fr) Anticorps multivalent
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA52885A (fr) Anticorps anti il-11ra
MA52152A (fr) Anticorps
MA50352A (fr) Anticorps multispécifiques
MA51903A (fr) Formulations d'anticorps b7-h4
MA51134A (fr) Anticorps anti-alpha-synucléine
MA49250A (fr) Nouveaux anticorps anti-cd3
MA55285A (fr) Anticorps ciblant c5ar
MA51212A (fr) Anticorps neutralisant les polyomavirus
MA44236A (fr) Anticorps anti-tgfbêta 2
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
MA56466A (fr) Anticorps anti-epha4
MA54312A (fr) Anticorps à domaine unique ciblant cll-1
MA51135A (fr) Anticorps anti-alpha-synucléine
MA50654A (fr) Anticorps anti-pacap
MA55705A (fr) Anticorps bispécifiques